Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

News SummaryMost relevantAll newsSector news 

ISIS Pharmaceuticals, Inc. : Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call

05/02/2013 | 01:00pm US/Eastern

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

    What:   Isis Pharmaceuticals' First Quarter 2013
            Financial Results and Highlights Conference

    When:   Tuesday, May 7, 2013 at 4:30 p.m. ET /1:30
            p.m. PT

    Where: www.isispharm.com

    How:    Live on the Internet.  Simply log onto our Web
            site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.


Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO(TM), in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.


This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics(TM) is a trademark of Regulus Therapeutics Inc. KYNAMRO(TM) is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals Inc.

React to this article
09/11DJIsis Pharmaceuticals Expands Partnership with AstraZeneca
09/11DJIsis Pharmaceuticals Expands Partnership with AstraZeneca
09/11 ASTRAZENECA : Isis-AstraZeneca Collaboration For Antisense Drugs Gets HSR Cleara..
09/11 ISIS PHARMACEUTICALS' : Collaboration to Discover and Develop Antisense Drugs fo..
09/03 ISIS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
08/12 ISIS PHARMACEUTICALS : AstraZeneca and Isis Pharmaceuticals to Discover and Deve..
08/12 ISIS PHARMACEUTICALS : Reports Financial Results And Highlights For Second Quart..
08/06 ISIS PHARMACEUTICALS : Excaliard Pharmaceuticals, Isis Pharmaceuticals Assigned ..
08/06 Isis Reveals Positive Data from KYNAMRO (mipomersen sodium) FOCUS FH Phase 3 ..
08/05 ISIS PHARMACEUTICALS : Reports Data from ISIS-TTR Rx in patients with Transthyre..